News

PRIMABS™-Dx in Multiple Myeloma – NUS Singapore

March, 2026, In Singapore, Eutropics today announced a research collaboration with the National University of Singapore (NUS) to evaluate the company’s PRIMAB™ functional biomarker platform in Multiple Myeloma. The partnership will explore how PRIMAB’s predictive insights into tumor cell apoptosis can inform individualized therapeutic strategies for patients with this complex hematologic cancer. The study will be led by Dr. Stephen Chong, a leading investigator in cancer cell physiology and mechanisms of drug response at NUS. Dr. Chong’s expertise complements Eutropics’ mission to translate systems-level understanding of cell death regulation into clinical tools that guide precision oncology. This collaboration represents an important step in extending the PRIMAB platform to Multiple Myeloma,

In October 2025, a publication in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) described Eutropics’ PRIMABS™ conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict response to BH3‑mimetics. Independent research groups are now citing this work in the context of BH3 profiling and functional precision oncology, underscoring PRIMABS™ potential as a clinically deployable companion diagnostic for apoptosis‑targeted therapies.

April, 2025, Eutropics Protein/Protein interaction detectors platform is published in “Cancers” DOI: 10.3390/cancers17111852. In this We describe a new diagnostics platform based on a novel panel of antibody-based reagents that have significant research utility and potential clinical utility for the prediction of drug treatment responses or in diagnosing mechanisms underlying treatment resistance in both solid and blood cancers. There is a well-established scientific hypothesis regarding the significance of mitochondrial priming as a functional predictor of cancer cell response to drug-induced apoptosis signaling presented.

December, 2024, in the United States, Eutropics and the Keck School of Medicine of the University of Southern California (USC) entered a research collaboration with the to evaluate its PRIMAB™ Dx diagnostic platform in Acute Myeloid Leukemia (AML). The study aims to assess how PRIMAB’s functional biomarker approach can help predict patient response to targeted and combination therapies in AML, a disease with considerable heterogeneity and unmet clinical need. The study will be led by Dr. Kevin Kelly, Professor of Clinical Medicine and an expert in hematologic malignancies at Keck/USC. Dr. Kelly’s research focuses on improving clinical outcomes for patients with AML through precision-based treatment strategies, making this collaboration a strong alignment with Eutropics’ mission to translate functional diagnostics into real-world clinical impact “This initiative expands the clinical reach of PRIMAB Dx into AML, where functional measures of treatment susceptibility may significantly enhance therapeutic decision-making,” said Michael Cardone. “We’re honored to collaborate with Dr. Kelly and his team as we work to bring more predictive, actionable tools to oncologists and their patients.” This partnership continues Eutropics’ strategy of advancing the PRIMAB platform across a range of hematologic cancers through leading academic collaborations.

September, 2024, Eutropics Pharmaceuticals is pleased to announce an extension of its long-standing research collaboration with the University of Texas MD Anderson Cancer Center, focused on advancing the PRIMAB™ functional biomarker platform in Acute Myeloid Leukemia (AML). The renewed MTA builds on more than a decade of joint research aimed at translating insights into apoptosis regulation and drug response into actionable diagnostic tools for clinical use. The ongoing studies are led by Dr. Bing Carter of MD Anderson’s AML research group, a recognized leader in AML biology and therapeutic development. Together with Eutropics, Dr. Carter’s team is working to refine and validate functional measures that may help predict therapeutic response and improve patient outcomes. This collaboration with MD Anderson has been foundational in the evolution and clinical translation of the PRIMAB platform.

May, 2023, Eutropics has entered an exploratory research agreement with Massachusetts General Brigham, a teaching hospital of Harvard Medical School, to support application of the PRIMABS™-Dx platform in tumors associated with Neurofibromatosis Type 1 (NF1). As part of this collaboration, Eutropics and the laboratory of Dr. James A. Walker, Assistant Professor of Neurology, will generate CRISPR‑engineered apoptotic signaling modified cell lines to model resistance mechanisms in NF1‑associated tumors, including those treated with currently used drugs. These tools will enable functional profiling of apoptotic signaling and anti-apoptotic BCL‑2 family proteins, with the goal of better defining how and when to target resistance factors in NF1‑driven solid tumors.

June 2019, 1Eutropics Pharmaceuticals has been awarded highly competitive funding from MassVentures’ SBIR Targeted Technologies (START) program to support commercialization of the next generation of the PraediCare Dx™ predictive cancer diagnostics platform. The non‑dilutive START Stage III grant builds on earlier Stage I and II awards. Backed by these competitive, non‑dilutive grants, Eutropics has evolved from legacy, Praedicare-Dx™diagnostics to Heterodimer Specific mAb‑Dx, a next‑generation conformation‑specific antibody platform that directly measures mitochondrial priming to de‑risk oncology pipelines and enable smarter patient selection.

2019 –AASCO Annual Meeting (Chicago)
Eutropics presented a poster titled “Identifying Bcl-2 family protein dependencies in tumors using dimerization specific antibody biomarkers as a method for predicting response to apoptosis inducing therapies.”eCancer Res (2019) 79 (13_Supplement): 3164. https://doi.org/10.1158/1538-7445.AM2019-3164

2019 – AACR Annual Meeting (Atlanta)
Eutropics presented a poster titled “Identifying Bcl-2 family protein dependencies in tumors using dimerization specific antibody biomarkers as a method for predicting response to apoptosis inducing therapies.”eCancer Res (2019) 79 (13_Supplement): 3164. https://doi.org/10.1158/1538-7445.AM2019-3164

September, 2018, Eutropics Pharmaceuticals has been selected for a prestigious NIH/NCI SBIR Phase IIB Bridge Award providing 3 million dollars in non‑dilutive matching funds,This award is designed to bridge the critical gap between completion of Phase II SBIR work and market adoption. Leveraging lessons from our legacy PraediCare-Dx™ work, Eutropics’ next generation Heterodimer Specific mAb-Dx platform—is being advanced commercially.